Back

Evolocumab treatment in paediatric patients with homozygous familial hypercholesterolaemia: the Trial Assessing long-term Use of PCSK9 inhibition in Subjects with Genetic LDL disorders (TAUSSIG)

28 August 2017 (12:12 - 12:21)
Organised by:
Congress Presentation Part of: Lipid lowering therapy in primary cardiovascular prevention Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Frederick Raal

University of the Witwatersrand, Johannesburg (South Africa)

8 More presentations in this session

Presentation thumbnail
Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes
Assistant Professor J. Rana (Oakland, US)
Abstract Slides Video
Presentation thumbnail
Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study
Doctor M. Leening (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Effects of morning versus evening statin therapy on lipid profile: A systematic review and meta-analysis
Doctor P. Penson (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Familial hypercholesterolemia: development of a next generation sequencing approach to the disease
Associate Professor R. Marcucci (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Comprehensive genotyping and phenotyping in patients with severe hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering therapy in primary cardiovascular prevention

The Event

Event poster

ESC Congress 2017

28 August 2017 12:12 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources